251 active not recruiting. 251 Phase 1, 101 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 251 | Active not recruiting 251 |
| Phase 2 | 101 | Active not recruiting 101 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI [99mTc]Tc-HYNIC-FAPI - Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic | Phase 1 | Active not recruiting | Tomsk National Research Medical Center of the Russian Academy of Sciences | 15 | 2026-02-26 | 2026-06-25 |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer narmafotinib ascending doses, narmafotinib dose comparison - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Amplia Therapeutics Limited | 67 | 2025-08-18 | 2026-05-05 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors BL-M05D1 - Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | SystImmune Inc. | 160 | 2025-07-30 | 2026-08-05 |
| A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors SH006 - Liver Cancer | Phase 1 | Active not recruiting | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 50 | 2025-07-01 | 2026-01-23 |
| Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Intravenous esketamine using Dixon's up-and-down sequential method, Intravenous the dose of esketamine ED95, Intravenous fentanyl 1 μg∙kg-1 - Hepatic Neoplasm, Hepatic Cancer | Phase 1 / Phase 2 | Active not recruiting | The First Affiliated Hospital of Xiamen University | 79 | 2025-06-29 | 2025-09-11 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Study for AZD4360 in Participants With Advanced Solid Tumours AZD4360 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 31 | 2025-04-29 | 2026-07-31 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 1 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 6 | 2025-04-03 | 2026-07-20 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB186748, Cetuximab, GEMNabP - Solid Tumors | Phase 1 | Active not recruiting | Incyte Corporation | 30 | 2025-03-27 | 2026-08-25 |
| JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC JAB-21822, standard second-line chemotherapy, Bevacizumab - Colorectal Cancer | Phase 1 | Active not recruiting | Jian Li | 30 | 2025-03-20 | 2026-01-08 |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer Onvansertib, NALIRIFOX - Pancreatic Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Kansas Medical Center | 16 | 2025-02-17 | 2026-09-25 |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors BMS-986490, Bevacizumab - Advanced Solid Tumors | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 360 | 2025-02-12 | 2026-09-01 |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) M9140 - Solid Tumors, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 184 | 2025-01-29 | 2026-10-22 |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors IPH4502 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Innate Pharma | 145 | 2025-01-24 | 2026-07-27 |
| Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab SD-101, Cryotherapy, Tremelimumab - Hepatocellular Carcinoma | Phase 1 | Active not recruiting | University of California, San Diego | 16 | 2025-01-03 | 2026-07-28 |
| Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum | Phase 1 | Active not recruiting | Arjun Mittra | 9 | 2024-12-31 | 2026-10-09 |
Showing 20 of 251. Sign in to see all of them.
Colorectal Neoplasms (103) · Pancreatic Neoplasms (73) · Carcinoma, Non-Small-Cell Lung (65) · Stomach Neoplasms (61) · Ovarian Neoplasms (42) · Carcinoma, Hepatocellular (37) · Melanoma (33) · Esophageal Neoplasms (31) · Neoplasm Metastasis (31) · Neoplasms (28) · Breast Neoplasms (27) · Colonic Neoplasms (27) · Squamous Cell Carcinoma of Head and Neck (27) · Lung Neoplasms (25) · Carcinoma, Renal Cell (21)
Digestive System Diseases (250) · Neoplasms by Site (245) · Neoplasms (223) · Gastrointestinal Diseases (175) · Gastrointestinal Neoplasms (168) · Intestinal Diseases (118) · Intestinal Neoplasms (116) · Colonic Diseases (113) · Rectal Diseases (109) · Neoplasms by Histologic Type (108) · Endocrine Gland Neoplasms (104) · Endocrine System Diseases (104) · Neoplasms, Glandular and Epithelial (92) · Carcinoma (90)
pembrolizumab (26) · Gemcitabine (21) · Nivolumab (19) · Fluorouracil (18) · Bevacizumab (17) · Specimen Handling (16) · Leucovorin (15) · Magnetic Resonance Spectroscopy (15) · Cetuximab (14) · Oxaliplatin (14) · Biopsy (13) · Paclitaxel (13) · 130-nm albumin-bound paclitaxel (12) · Carboplatin (12) · Irinotecan (12)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (16) · AstraZeneca (7) · Eli Lilly and Company (7) · City of Hope Medical Center (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Memorial Sloan Kettering Cancer Center (4) · Novartis Pharmaceuticals (4) · TORL Biotherapeutics, LLC (4) · University of Southern California (4) · AbbVie (3) · Baylor College of Medicine (3) · GlaxoSmithKline (3) · Ono Pharmaceutical Co., Ltd. (3) · Amgen (2)
United States (182) · Spain (52) · China (46) · France (44) · Australia (41) · South Korea (41) · Canada (39) · Japan (35) · Italy (31) · United Kingdom (29) · Germany (24) · Belgium (22) · Taiwan (18) · Netherlands (16) · Denmark (12)
Project Leader (3) · Caroline Labib, PharmD (2) · Daneng Li (2) · David Hong, MD (2) · Jeremie Calais (2) · Liza C Villaruz (2) · Marwan G Fakih (2)
PMID 37788341, PMID 22225488, PMID 22285199, PMID 30514390, PMID 31345267, PMID 32002290, PMID 32771088, PMID 32846060, PMID 32846061, PMID 33986124, PMID 34088726, PMID 34161704, PMID 34491815, PMID 35041493, PMID 35167329, PMID 35264434, PMID 35404402, PMID 35507536, PMID 35658005, PMID 35688554, PMID 35690072, PMID 35756843, PMID 35929986, PMID 35930972, PMID 36108661, PMID 36122315, PMID 36307845, PMID 36399068, PMID 36546659, PMID 36624315, PMID 36657661, PMID 37099736, PMID 37265412, PMID 37327468, PMID 37589506, PMID 37590355, PMID 37592303, PMID 37598000, PMID 37611121, PMID 37689733, PMID 37848297, PMID 37872225, PMID 37934000, PMID 37939124, PMID 38052910, PMID 38204489, PMID 38236249, PMID 38314087, PMID 38316518, PMID 38504015
2023 (13), 2019 (5), P30CA033572 (4), 2025 (3), P30CA014089 (3), UM1CA186644 (3), UM1CA186690 (3), UM1CA186709 (3), 2017 (2), 2018 (2), P30CA015083 (2), P30CA016672 (2), U01CA062490 (2), UM1CA186689 (2), UM1CA186716 (2)